<DOC>
	<DOCNO>NCT00660231</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine bexarotene , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study give gemcitabine together bexarotene see well work treat patient progressive refractory stage IB , stage II , stage III , stage IV cutaneous T-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Gemcitabine Bexarotene Treating Patients With Progressive Refractory Stage IB , Stage II , Stage III , Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Confirm feasibility efficacy combination gemcitabine hydrochloride bexarotene patient cutaneous T-cell lymphoma whose disease longer control skin-directed therapy least one prior systemic therapy . Secondary - Determine rate objective disease control define complete response ( CR ) , clinical complete response ( CCR ) , partial response ( PR ) , stable disease ( SD ) 6 month determine Objective Primary Disease Response Evaluation Criteria ( OPDREC ) . - Evaluate duration durability objective disease response ( CR , CCR PR ) determine OPDREC criterion . - Evaluate time objective disease response . - Determine safety combination term adverse event , clinical laboratory data , physical examination , rate neutropenic fever sepsis , blood transfusion , treatment compliance . - Determine time objective disease progression . - Determine time treatment failure . - Determine change baseline Severity-Weighted Assessment Tool ( SWAT ) value , Erythroderma SWAT value , Pruritus Visual Analogue Scale , ECOG performance status . - Determine proportion disease control , response , progression determine RECIST criterion . - Evaluate proportion patient clear Sézary cell blood bone marrow . - Measure change patient assess Quality Life use Skindex 29 EORTC QLQ-30 . OUTLINE : This multicenter study . Patients receive gemcitabine hydrochloride IV day 1 8 oral bexarotene daily day 1-21 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . After 4 course study therapy , patient respond disease receive oral bexarotene alone daily disease progression treatment longer tolerate . Patients complete quality life questionnaire baseline , study therapy , completion study treatment . After completion study treatment , patient follow every 2 month 5 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell lymphoma ( CTCL ) include variant ( e.g. , mycosis fungoides Sézary syndrome ) CTCL stage IB , IIA , IIB , III IVA disease No visceral involvement ( i.e. , stage IVB disease ) Lymphadenopathy allow Patients must develop progressive disease receive refractory least 1 course prior standard , systemic , skindirected therapy ( e.g. , interferon , chemotherapy , denileukin diftitox [ Ontak® ] ) No CD30 + ( Ki1+ve ) anaplastic large cell lymphoma PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 6 month Hemoglobin ≥ 9.0 g/dL ( transfusion and/or erythropoietin allow ) ANC &gt; 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Total bilirubin ≤ 1.25 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Serum creatinine ≤ 2 time ULN No clinically significant active infection No uncontrolled diabetes mellitus No excessive alcohol consumption No biliary tract disease No history pancreatitis HIV negative Hepatitis B C negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation No malignancy within past 5 year except curatively treat basal squamous cell skin cancer , cervical epithelial neoplasm CIN1 , carcinoma situ No significant medical psychiatric condition would preclude study compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior investigational agent More 2 week since prior topical steroid 4 week since prior systemic steroid Local radiotherapy may give isolated symptomatic tumour nodule require immediate treatment 2 week prior study drug No prior treatment bexarotene ( Targretin® ) No concurrent anticancer therapy No concurrent investigational agent No concurrent drug therapy medication elevate triglyceride cause pancreatic toxicity ( e.g. , gemfibrozil ) No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IB mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IB cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>